BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32213210)

  • 1. Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Int Braz J Urol; 2020; 46(4):545-556. PubMed ID: 32213210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naïve Cases.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Panunzio A; De Michele M; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Urol Int; 2019; 103(4):415-422. PubMed ID: 31466070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10 ng/ml: results of 564 consecutive cases.
    Porcaro AB; Tafuri A; Sebben M; Shakir A; Novella G; Pirozzi M; Processali T; Rizzetto R; Amigoni N; Tiso L; Cerrato C; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Ther Adv Urol; 2019; 11():1756287219868604. PubMed ID: 31452688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Mariotto A; Brunelli M; Cerruto MA; Cacciamani GE; Migliorini F; Siracusano S; Artibani W
    World J Urol; 2020 Apr; 38(4):957-964. PubMed ID: 31154465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors.
    Tafuri A; Sebben M; Novella G; Pirozzi M; Processali T; Shakir A; Rizzetto R; Amigoni N; Bernasconi R; Brunelli M; Cerruto MA; Siracusano S; Antonelli A; Artibani W; Porcaro AB
    Arab J Urol; 2020 May; 18(3):148-154. PubMed ID: 33029424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer.
    Porcaro AB; Novella G; Molinari A; Terrin A; Minja A; De Marco V; Martignoni G; Brunelli M; Cerruto MA; Curti P; Cavalleri S; Artibani W
    Urol Int; 2015; 94(3):270-85. PubMed ID: 25170543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate volume index stratified prostate cancer risk in patients elected to a first random biopsy set.
    Porcaro AB; Corsi P; de Luyk N; Sebben M; Tafuri A; Bizzotto L; Cacciamani G; De Marchi D; Processali T; Mattevi D; Novella G; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Tumori; 2017 Jul; 103(4):374-379. PubMed ID: 28291903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
    Zheng S; Jiang S; Chen Z; Huang Z; Shi W; Liu B; Xu Y; Guo Y; Yang H; Li M
    PLoS One; 2019; 14(11):e0218645. PubMed ID: 31743339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.
    Servian P; Celma A; Planas J; Placer J; de Torres IM; Morote J
    Prostate; 2016 Dec; 76(16):1501-1506. PubMed ID: 27404228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set.
    Porcaro AB; Tafuri A; Novella G; Sebben M; Mariotto A; Inverardi D; Corsi P; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Brunelli M; Balzarro M; Siracusano S; Artibani W
    Urol Int; 2018; 100(4):456-462. PubMed ID: 29672311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer.
    Yu HJ; Lai MK
    Urology; 1998 May; 51(5A Suppl):125-30. PubMed ID: 9610567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
    Dell'Atti L
    J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study.
    Park DH; Yu JH
    Transl Cancer Res; 2023 Mar; 12(3):502-514. PubMed ID: 37033352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Volume Index Associates with a Decreased Risk of Prostate Cancer: Results of a Large Cohort of Patients Elected to a First Biopsy Set.
    Porcaro AB; Novella G; Cacciamani G; De Marchi D; Corsi P; De Luyk N; Bizzotto L; Processali T; Cerasuolo M; Tamanini I; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Urol Int; 2017; 98(1):22-27. PubMed ID: 27376763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men.
    Ishimura T; Sakai I; Hara I; Eto H; Miyake H
    Int J Clin Oncol; 2004 Feb; 9(1):47-50. PubMed ID: 15162826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges.
    Meshref AW; Bazinet M; Trudel C; Aronson S; Peloquin F; Nachabe M; Dessureault J; Aprikian AG; Begin LR; Elhilali MM
    Urology; 1995 Jun; 45(6):972-9. PubMed ID: 7539562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.